Clinical trials located in


Zabrze city is located in Poland. Currently, 13 clinical trials are being conducted in this city.

Zabrze, located in Poland’s Silesian Voivodeship, is a city steeped in industrial heritage, particularly known for its coal mining history. Established in the 13th century, it became a significant center for coal mining and steel production in the 19th and 20th centuries. Zabrze is home to the Guido Mine, which is one of the deepest coal mines in Europe open to visitors, descending to 320 meters below the surface. The city also boasts the unique Museum of Mining, showcasing the industry’s history. Additionally, Zabrze’s identity is enriched by its vibrant cultural scene, including numerous theaters and music venues.

  • CT-EU-00112165

    Exploring the safety and effectiveness of somapacitan for growth in children

    The study is focused on evaluating the safety and effectiveness of somapacitan, a new growth hormone treatment. This treatment, given once a week through an injection, aims to assist children who were born small for their gestational age or have been diagnosed with Turner syndrome, Noonan syndrome, or idiopathic short stature. Over a three-year period, the study will monitor for any adverse events or side effects, particularly observing how somapacitan impacts children with these specific  conditions. Participants will receive thorough training from the study team on administering the medication at home. This research is vital for potentially improving treatment and quality of life for children facing growth challenges, emphasizing participant safety and well-being throughout the study process.

  • Crovalimab for atypical hemolytic uremic syndrome

    A research study is being conducted to determine the effectiveness and safety of a medication called Crovalimab for adult and adolescent patients suffering from atypical hemolytic uremic syndrome (aHUS), a condition affecting the blood and blood vessels. The study involves the participation of 80 individuals and mainly aims at providing treatment. Crovalimab is administered differently based on the participant’s weight. Outcome measures will be analyzed from baseline up to Week 25, focusing on the complete TMA response, dialysis status, kidney disease stage and several other factors. The main goal is to improve the condition of patients suffering from aHUS and to formulate an effective treatment plan.

  • A study on crovalimab in children with aHUS

    This study is about testing a medicine called Crovalimab in children who have a blood and kidney disease called Atypical Hemolytic Uremic Syndrome or aHUS for short. This trial is going to answer two key questions – is Crovalimab effective in treating aHUS and is it safe for kids to use without damaging side effects? The doctors will also be looking at how the child’s body handles the medicine, like how it gets absorbed, breaks down, and gets removed from their body. This helps figure out how often the medicine should be given for it to work best.

  • Satralizumab treatment study for encephalitis patients

    This study is checking how well a medicine called Satralizumab works for people with two specific types of brain inflammation (swelling), known as NMDAR and LGI1 encephalitis. The study aims to see how safe this medicine is, how patient body absorbs, distributes, and gets rid of it, and how it affects the patient condition. This study involves people from different places and is controlled, which means some people will get the medicine and others will get placebo without knowing which they are taking. The study will be focused if the medicine can stop the seizures for at least 6 weeks. During the study will be provided different tests to check a physical and mental health.

  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Study on carfilzomib effect on children’s leukemia

    This clinical trial focuses on children who face the difficult situation of acute lymphoblastic leukemia (ALL), a type of blood cancer. When cancer returns or does not respond to standard treatments, doctors call it relapsed or refractory, and it can be difficult to treat. The study is evaluating a drug called carfilzomib, which is being tested alongside common chemotherapy drugs. The drugs used in the clinical trial include carfilzomib, dexamethasone, mitoxantrone, PEG-asparaginase, vincristine, Intrathecal Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-mercaptopurine, cyclophosphamide, cytarabine, and daunorubicin. The process has two main goals. First, he wants to find an appropriate dose of carfilzomib that is safe for children. This is significant because finding the right dose means balancing effectiveness with minimizing side effects. Once a safe dose is determined, the second part of the study begins. This part is about seeing how well carfilzomib works when it is part of a treatment regimen. Doctors and researchers will carefully monitor the children’s response to treatment. They will check whether the cancer responds to the new approach and how the children’s bodies cope with it. They will also track any side effects to ensure your treatment is safe.

  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainSwedenUnited Kingdom
  • Studying retatrutide for treating obesity and heart disease

    This research study is about a medicine called Retatrutide (also known as LY3437943), which will be tested on people who have obesity and heart disease. The way this study will work is that some people will be given Retatrutide once a week, while others will be given a placebo, which doesn’t have any medicine in it. By doing this, the researchers can see if Retatrutide helps to improve health and if it is safe to use. The study will run for just over two years. AUC is a way for the study to measure the effect of Retatrutide on your body.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.


See more clinical trials in other cities in Poland: